The historical rank and industry rank for Biomarin Pharmaceutical's Cyclically Adjusted PS Ratio or its related term are showing as below:
BMRN'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 7.9 Med: 17.25 Max: 44.11
Current: 8.02
During the past years, Biomarin Pharmaceutical's highest Cyclically Adjusted PS Ratio was 44.11. The lowest was 7.90. And the median was 17.25.
BMRN's Cyclically Adjusted PS Ratio is ranked worse than 60.08% of 506
companies
in the Biotechnology industry
Industry Median: 5.395
vs BMRN: 8.02
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Biomarin Pharmaceutical's adjusted revenue per share data for the three months ended in Mar. 2024 was $3.256. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $10.24 for the trailing ten years ended in Mar. 2024.
Shiller PE for Stocks: The True Measure of Stock Valuation
Biomarin Pharmaceutical Cyclically Adjusted PS Ratio Historical Data
The historical data trend for Biomarin Pharmaceutical's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Biomarin Pharmaceutical Cyclically Adjusted PS Ratio Chart
Competitive Comparison of Biomarin Pharmaceutical's Cyclically Adjusted PS Ratio
For the Biotechnology subindustry, Biomarin Pharmaceutical's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biomarin Pharmaceutical's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Biomarin Pharmaceutical's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Biomarin Pharmaceutical's Cyclically Adjusted PS Ratio falls into.
Biomarin Pharmaceutical Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Biomarin Pharmaceutical (NAS:BMRN) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Biomarin Pharmaceutical Cyclically Adjusted PS Ratio Related Terms
Thank you for viewing the detailed overview of Biomarin Pharmaceutical's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Biomarin Pharmaceutical (Biomarin Pharmaceutical) Business Description
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the U.S. in 2023.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BMRN has been successfully added to your 